Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Mini-Review Article

Potential Therapeutic Strategies for Targeting Y-Box-Binding Protein 1 in Cancers

Author(s): Jia-Wei Yang, Chao Sun, Qiu-Yang Jin, Xing-Hui Qiao and Xiu-Li Guo*

Volume 21, Issue 11, 2021

Published on: 31 August, 2021

Page: [897 - 906] Pages: 10

DOI: 10.2174/1568009621666210831125001

Price: $65

Abstract

As one of the most conservative proteins in evolution, Y-box-binding protein 1 (YB-1) has long been considered as a potential cancer target. YB-1 is usually poorly expressed in normal cells and exerts cellular physiological functions such as DNA repair, pre-mRNA splicing and mRNA stabilizing. In cancer cells, the expression of YB-1 is up-regulated and undergoes nuclear translocation and contributes to tumorigenesis, angiogenesis, tumor proliferation, invasion, migration and chemotherapy drug resistance. During the past decades, a variety of pharmacological tools such as siRNA, shRNA, microRNA, circular RNA, lncRNA and various compounds have been developed to target YB-1 for cancer therapy. In this review, we describe the physiological characteristics of YB-1 in detail, highlight the role of YB-1 in tumors and summarize the current therapeutic methods for targeting YB-1 in cancer.

Keywords: Y-box-binding protein 1, cancer, nuclear translocation model, siRNA, shRNA, microRNA, circular RNA, lncRNA.

Next »
Graphical Abstract

[1]
Lindquist, J.A.; Mertens, P.R. Cold shock proteins: From cellular mechanisms to pathophysiology and disease. Cell Commun. Signal., 2018, 16(1), 63.
[http://dx.doi.org/10.1186/s12964-018-0274-6] [PMID: 30257675]
[2]
Johnson, T.G.; Schelch, K.; Mehta, S.; Burgess, A.; Reid, G. Why be one protein when you can affect many? The multiple roles of YB-1 in lung cancer and mesothelioma. Front. Cell Dev. Biol., 2019, 7, 221.
[http://dx.doi.org/10.3389/fcell.2019.00221] [PMID: 31632972]
[3]
(a)Zhang, C.; Yin, T.; Tao, R.; Xiao, B.; Chen, J.; Li, Z.; Miao, X.; Peng, Q.; Sun, L.; Zhang, W.; Ren, J.; Zhang, Z.; Zhang, Y.; Li, X.; Zhang, W. Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: A meta-analysis. Cancer Manag. Res., 2019, 11, 4391-4402.
(b)Jiang, L.; Yuan, G-L.; Liang, Q-L.; Zhang, H-J.; Huang, J.; Cheng, S-A.; Peng, X-X. Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: a meta-analysis. Oncotarget, 2017, 8(33), 55613-55621.
(c)Shinkai, K.; Nakano, K.; Cui, L.; Mizuuchi, Y.; Onishi, H.; Oda, Y.; Obika, S.; Tanaka, M.; Katano, M. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models. Int. J. Cancer, 2016, 139(2), 433-445.
[http://dx.doi.org/10.2147/CMAR.S195243] [PMID: 31191002] [http://dx.doi.org/10.18632/oncotarget.14732] [PMID: 28903448] [http://dx.doi.org/10.1002/ijc.30075] [PMID: 26939718]
[4]
(a)Kuwano, M.; Shibata, T.; Watari, K.; Ono, M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci., 2019, 110(5), 1536-1543.
(b)Shiota, M.; Bishop, J.L.; Takeuchi, A.; Nip, K.M.; Cordonnier, T.; Beraldi, E.; Kuruma, H.; Gleave, M.E.; Zoubeidi, A. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget, 2015, 6(11), 9086-9098.
[http://dx.doi.org/10.1111/cas.14006] [PMID: 30903644] [http://dx.doi.org/10.18632/oncotarget.3602] [PMID: 25871401]
[5]
(a)Wang, W.; Wang, H.J.; Wang, B.; Li, Y.; Qin, Y.; Zheng, L.S.; Zhou, J.S.; Qu, P.H.; Shi, J.H.; Zhang, H.S. The role of the Y box binding protein 1 C-terminal domain in vascular endothelial cell proliferation, apoptosis, and angiogenesis. DNA Cell Biol., 2016, 35(1), 24-32.
(b)Yadav, B.S.; Singh, S.; Shaw, A.K.; Mani, A. Structure prediction and docking-based molecular insights of human YB-1 and nucleic acid interaction. J. Biomol. Struct. Dyn., 2016, 34(12), 2561-2580.
[http://dx.doi.org/10.1089/dna.2015.2908] [PMID: 26430912] [http://dx.doi.org/10.1080/07391102.2015.1124050] [PMID: 26609765]
[6]
(a)Murugesan, S.N.; Yadav, B.S.; Maurya, P.K.; Chaudhary, A.; Singh, S.; Mani, A. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas. J. Biosci., 2019, 44(2), 27.
(b)Zhu, X.; Chen, X.; Xu, W. Expression of YB1 and CD44 and its relationship with platinum-resistant epithelial ovarian cancer. Current Advances in Obstetrics and Gynecology, 2016, 25(3), 175-177.
(c)Xu, G.; Li, Z.; Wang, L.; Chen, F.; Chi, Z.; Gu, M.; Li, S.; Wu, D.; Miao, J.; Zhang, Y.; Hao, L.; Fan, Y. Label-free quantitative proteomics reveals differentially expressed proteins in high risk childhood acute lymphoblastic leukemia. J. Proteomics, 2017, 150, 1-8.
(d)Liang, C.; Ma, Y.; Yong, L.; Yang, C.; Wang, P.; Liu, X.; Zhu, B.; Zhou, H.; Liu, X.; Liu, Z. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma. Cancer Sci., 2019, 110(1), 166-179.
(e)Shiota, M.; Fujimoto, N.; Imada, K.; Yokomizo, A.; Itsumi, M.; Takeuchi, A.; Kuruma, H.; Inokuchi, J.; Tatsugami, K.; Uchiumi, T.; Oda, Y.; Naito, S. Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J. Natl. Cancer Inst., 2016, 108(7)
[http://dx.doi.org/10.1007/s12038-019-9848-8] [PMID: 31180040] [http://dx.doi.org/10.1016/j.jprot.2016.08.014] [PMID: 27569049] [http://dx.doi.org/10.1111/cas.13875] [PMID: 30426615] [http://dx.doi.org/10.1093/jnci/djw005] [PMID: 26857528]
[7]
(a)Lim, J.P.; Shyamasundar, S.; Gunaratne, J.; Scully, O.J.; Matsumoto, K.; Bay, B.H. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro. BMC Cancer, 2017, 17(1), 201.
(b)Lyabin, D.N.; Ovchinnikov, L.P. Selective regulation of YB-1 mRNA translation by the mTOR signaling pathway is not mediated by 4E-binding protein. Sci. Rep., 2016, 6, 22502.
(c)Li, S.; Zhao, Q.; Wang, B.; Yuan, S.; Wang, X.; Li, K. Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation. Phytother. Res., 2018, 32(8), 1530-1536.
[http://dx.doi.org/10.1186/s12885-017-3187-7] [PMID: 28302118] [http://dx.doi.org/10.1038/srep22502] [PMID: 26931209] [http://dx.doi.org/10.1002/ptr.6081] [PMID: 29635751]
[8]
Meyer, N.; Schumacher, A.; Coenen, U.; Woidacki, K.; Schmidt, H.; Lindquist, J.A.; Mertens, P.R.; Zenclussen, A.C. Y-Box binding protein 1 expression in trophoblast cells promotes fetal and placental development. Cells, 2020, 9(9), E1942.
[http://dx.doi.org/10.3390/cells9091942] [PMID: 32842598]
[9]
Maurya, P.K.; Mishra, A.; Yadav, B.S.; Singh, S.; Kumar, P.; Chaudhary, A.; Srivastava, S.; Murugesan, S.N.; Mani, A. Role of Y box protein-1 in cancer: As potential biomarker and novel therapeutic target. J. Cancer, 2017, 8(10), 1900-1907.
[http://dx.doi.org/10.7150/jca.17689] [PMID: 28819388]
[10]
(a)Sangermano, F.; Delicato, A.; Calabrò, V. Y box binding protein 1 (YB-1) oncoprotein at the hub of DNA proliferation, damage and cancer progression. Biochimie, 2020, 179, 205-216.
(b)Lyabin, D.N.; Eliseeva, I.A.; Ovchinnikov, L.P. YB-1 protein: functions and regulation. Wiley Interdiscip. Rev. RNA, 2014, 5(1), 95-110.
[http://dx.doi.org/10.1016/j.biochi.2020.10.004] [PMID: 33058958] [http://dx.doi.org/10.1002/wrna.1200] [PMID: 24217978]
[11]
(a)Mehta, S.; Algie, M.; Al-Jabry, T.; McKinney, C.; Kannan, S.; Verma, C.S.; Ma, W.; Zhang, J.; Bartolec, T.K.; Masamsetti, V.P.; Parker, K.; Henderson, L.; Gould, M.L.; Bhatia, P.; Harfoot, R.; Chircop, M.; Kleffmann, T.; Cohen, S.B.; Woolley, A.G.; Cesare, A.J.; Braithwaite, A. Critical role for cold shock protein YB-1 in cytokinesis. Cancers (Basel), 2020, 12(9), E2473.
(b)Hessman, C.L.; Hildebrandt, J.; Shah, A.; Brandt, S.; Bock, A.; Frye, B.C.; Raffetseder, U.; Geffers, R.; Brunner-Weinzierl, M.C.; Isermann, B.; Mertens, P.R.; Lindquist, J.A. YB-1 Interferes with TNFα-TNFR binding and modulates progranulin-mediated inhibition of TNFα signaling. Int. J. Mol. Sci., 2020, 21(19), E7076.
(c)Yang, X-J.; Zhu, H.; Mu, S-R.; Wei, W-J.; Yuan, X.; Wang, M.; Liu, Y.; Hui, J.; Huang, Y. Crystal structure of a Y-box binding protein 1 (YB-1)-RNA complex reveals key features and residues interacting with RNA. J. Biol. Chem., 2019, 294(28), 10998-11010.
[http://dx.doi.org/10.3390/cancers12092473] [PMID: 32882852] [http://dx.doi.org/10.3390/ijms21197076] [PMID: 32992926] [http://dx.doi.org/10.1074/jbc.RA119.007545] [PMID: 31160337]
[12]
Guarino, A.M.; Troiano, A.; Pizzo, E.; Bosso, A.; Vivo, M.; Pinto, G.; Amoresano, A.; Pollice, A.; La Mantia, G.; Calabrò, V. Oxidative stress causes enhanced secretion of YB-1 protein that restrains proliferation of receiving cells. Genes (Basel), 2018, 9(10), E513.
[http://dx.doi.org/10.3390/genes9100513] [PMID: 30360431]
[13]
Gunasekaran, V.P.; Nishi, K.; Ravikumar, V.; Mathan, G. Nuclear shuttling of Y-box binding protein 1, its clinical relevance to cancer and as a therapeutic target. Bangladesh J. Pharmacol., 2016, 11(2), 501-524.
[http://dx.doi.org/10.3329/bjp.v11i2.26759]
[14]
Mehta, S.; McKinney, C.; Algie, M.; Verma, C.S.; Kannan, S.; Harfoot, R.; Bartolec, T.K.; Bhatia, P.; Fisher, A.J.; Gould, M.L.; Parker, K.; Cesare, A.J.; Cunliffe, H.E.; Cohen, S.B.; Kleffmann, T.; Braithwaite, A.W.; Woolley, A.G. Dephosphorylation of YB-1 is required for nuclear localisation during G2 phase of the cell cycle. Cancers (Basel), 2020, 12(2), E315.
[http://dx.doi.org/10.3390/cancers12020315] [PMID: 32013098]
[15]
Roßner, F.; Gieseler, C.; Morkel, M.; Royer, H.D.; Rivera, M.; Bläker, H.; Dietel, M.; Schäfer, R.; Sers, C. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis, 2016, 5, e187.
[http://dx.doi.org/10.1038/oncsis.2015.51] [PMID: 26779809]
[16]
Tanaka, T.; Kasai, M.; Kobayashi, S. Mechanism responsible for inhibitory effect of indirubin 3′-oxime on anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells. Exp. Cell Res., 2018, 370(2), 454-460.
[http://dx.doi.org/10.1016/j.yexcr.2018.07.009] [PMID: 29981748]
[17]
(a)Kretov, D.A.; Mordovkina, D.A.; Eliseeva, I.A.; Lyabin, D.N.; Polyakov, D.N.; Joshi, V.; Desforges, B.; Hamon, L.; Lavrik, O.I.; Pastré, D.; Curmi, P.A.; Ovchinnikov, L.P. Inhibition of transcription induces phosphorylation of YB-1 at Ser102 and its accumulation in the nucleus. Cells, 2019, 9(1), E104.
(b)Gieseler-Halbach, S.; Meltendorf, S.; Pierau, M.; Weinert, S.; Heidel, F.H.; Fischer, T.; Handschuh, J.; Braun-Dullaeus, R.C.; Schrappe, M.; Lindquist, J.A.; Mertens, P.R.; Thomas, U.; Brunner-Weinzierl, M.C. RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death Differ., 2017, 24(2), 371-383.
[http://dx.doi.org/10.3390/cells9010104] [PMID: 31906126] [http://dx.doi.org/10.1038/cdd.2016.141] [PMID: 28009354]
[18]
Budkina, K.S.; Zlobin, N.E.; Kononova, S.V.; Ovchinnikov, L.P.; Babakov, A.V. Cold Shock Domain Proteins: Structure and Interaction with nucleic acids. Biochemistry (Mosc.), 2020, 85(Suppl. 1), S1-S19.
[http://dx.doi.org/10.1134/S0006297920140011] [PMID: 32087051]
[19]
(a)Koike, K.; Uchiumi, T.; Ohga, T.; Toh, S.; Wada, M.; Kohno, K.; Kuwano, M. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett., 1997, 417(3), 390-394.
(b)Shi, J.H.; Cui, N.P.; Wang, S.; Zhao, M.Z.; Wang, B.; Wang, Y.N.; Chen, B.P. Overexpression of YB1 C-terminal domain inhibits proliferation, angiogenesis and tumorigenicity in a SK-BR-3 breast cancer xenograft mouse model. FEBS Open Bio, 2016, 6(1), 33-42.
[http://dx.doi.org/10.1016/S0014-5793(97)01296-9] [PMID: 9409758] [http://dx.doi.org/10.1002/2211-5463.12004] [PMID: 27047740]
[20]
Kosnopfel, C.; Sinnberg, T.; Schittek, B. Y-box binding protein 1--a prognostic marker and target in tumour therapy. Eur. J. Cell Biol., 2014, 93(1-2), 61-70.
[http://dx.doi.org/10.1016/j.ejcb.2013.11.007] [PMID: 24461929]
[21]
(a)Bledzka, K.; Schiemann, B.; Schiemann, W.P.; Fox, P.; Plow, E.F.; Sossey-Alaoui, K. The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer. Oncotarget, 2017, 8(61), 104072-104089.
(b)Mordovkina, D.A.; Kim, E.R.; Buldakov, I.A.; Sorokin, A.V.; Eliseeva, I.A.; Lyabin, D.N.; Ovchinnikov, L.P. Transportin-1-dependent YB-1 nuclear import. Biochem. Biophys. Res. Commun., 2016, 480(4), 629-634.
[http://dx.doi.org/10.18632/oncotarget.22009] [PMID: 29262622] [http://dx.doi.org/10.1016/j.bbrc.2016.10.107] [PMID: 27794479]
[22]
Bader, A.G.; Vogt, P.K. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol. Cell. Biol., 2005, 25(6), 2095-2106.
[http://dx.doi.org/10.1128/MCB.25.6.2095-2106.2005] [PMID: 15743808]
[23]
Tanaka, T.; Ohashi, S.; Kobayashi, S. Four nucleocytoplasmic-shuttling proteins and p53 interact specifically with the YB-NLS and are involved in anticancer reagent-induced nuclear localization of YB-1. Biochem. Biophys. Res. Commun., 2016, 478(3), 1363-1369.
[http://dx.doi.org/10.1016/j.bbrc.2016.08.129] [PMID: 27565728]
[24]
Okamoto, T.; Izumi, H.; Imamura, T.; Takano, H.; Ise, T.; Uchiumi, T.; Kuwano, M.; Kohno, K. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene, 2000, 19(54), 6194-6202.
[http://dx.doi.org/10.1038/sj.onc.1204029] [PMID: 11175333]
[25]
Tanabe, Y.; Nagatoishi, S.; Tsumoto, K. Thermodynamic characterization of the interaction between the human Y-box binding protein YB-1 and nucleic acids. Mol. Biosyst., 2015, 11(9), 2441-2448.
[http://dx.doi.org/10.1039/C5MB00184F] [PMID: 26126888]
[26]
Yamashita, T.; Higashi, M.; Momose, S.; Morozumi, M.; Tamaru, J-I. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. Int. J. Oncol., 2017, 51(2), 579-586.
[http://dx.doi.org/10.3892/ijo.2017.4031] [PMID: 28714514]
[27]
Ferreira, D.; Martins, B.; Soares, M.; Correia, J.; Adega, F.; Ferreira, F.; Chaves, R. Gene expression association study in feline mammary carcinomas. PLoS One, 2019, 14(8), e0221776.
[http://dx.doi.org/10.1371/journal.pone.0221776] [PMID: 31461477]
[28]
Ma, J.; Li, X.; Wu, G.; Yue, Z.; Wang, Z. Y-box-binding protein-1 and E-cadherin are potential prognostic factors in human bladder carcinoma. Int. J. Clin. Exp. Med., 2018, 11(12), 13743-13749.
[29]
Jin, X.; Qian, J.; Yu, D-J.; Guo, C-X.; Li, N.; Zhu, Q.; Zhao, Y. Expression of FOXC-2 and YB-1 in gastric carcinoma and its role in invasion and metastasis. Sichuan Da Xue Xue Bao Yi Xue Ban, 2018, 49(2), 215-220.
[PMID: 29737063]
[30]
Tiwari, A.; Iida, M.; Kosnopfel, C.; Abbariki, M.; Menegakis, A.; Fehrenbacher, B.; Maier, J.; Schaller, M.; Brucker, S.Y.; Wheeler, D.L.; Harari, P.M.; Rothbauer, U.; Schittek, B.; Zips, D.; Toulany, M. Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. Cancers (Basel), 2020, 12(10), E2795.
[http://dx.doi.org/10.3390/cancers12102795] [PMID: 33003386]
[31]
Lou, L.; Wang, J.; Lv, F.; Wang, G.; Li, Y.; Xing, L.; Shen, H.; Zhang, X. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP). Cell. Oncol., 2020.
[PMID: 32894437]
[32]
Prabhu, L.; Hartley, A-V.; Martin, M.; Warsame, F.; Sun, E.; Lu, T. Role of post-translational modification of the Y box binding protein 1 in human cancers. Genes Dis., 2015, 2(3), 240-246.
[http://dx.doi.org/10.1016/j.gendis.2015.05.001] [PMID: 30258867]
[33]
Heumann, A.; Kaya, Ö.; Burdelski, C.; Hube-Magg, C.; Kluth, M.; Lang, D.S.; Simon, R.; Beyer, B.; Thederan, I.; Sauter, G.; Izbicki, J.R.; Luebke, A.M.; Hinsch, A.; Jacobsen, F.; Wittmer, C.; Büscheck, F.; Höflmayer, D.; Minner, S.; Tsourlakis, M.C.; Schlomm, T.; Wilczak, W. Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. Sci. Rep., 2017, 7(1), 2056.
[http://dx.doi.org/10.1038/s41598-017-02279-x] [PMID: 28515422]
[34]
Chua, P.J.; Lim, J.P.; Guo, T.T.; Khanna, P.; Hu, Q.; Bay, B.H.; Baeg, G.H. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells. Int. J. Oncol., 2018, 53(6), 2579-2589.
[http://dx.doi.org/10.3892/ijo.2018.4557] [PMID: 30221675]
[35]
Kosnopfel, C.; Sinnberg, T.; Sauer, B.; Busch, C.; Niessner, H.; Schmitt, A.; Forchhammer, S.; Grimmel, C.; Mertens, P.R.; Hailfinger, S.; Dunn, S.E.; Garbe, C.; Schittek, B. YB-1 expression and phosphorylation regulate tumorigenicity and invasiveness in melanoma by influencing EMT. Mol. Cancer Res., 2018, 16(7), 1149-1160.
[http://dx.doi.org/10.1158/1541-7786.MCR-17-0528] [PMID: 29743296]
[36]
Ibrahim, W.N.; Doolaanea, A.A.; Bin Abdull Rasad, M.S.B. Effect of shRNA mediated silencing of YB-1 protein on the expression of matrix collagenases in malignant melanoma cell in vitro. Cells, 2018, 7(1), E7.
[http://dx.doi.org/10.3390/cells7010007] [PMID: 29320405]
[37]
Nagasu, S.; Sudo, T.; Kinugasa, T.; Yomoda, T.; Fujiyoshi, K.; Shigaki, T.; Akagi, Y. Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer. Oncol. Rep., 2019, 41(5), 2889-2896.
[http://dx.doi.org/10.3892/or.2019.7038] [PMID: 30864697]
[38]
Wang, H.; Sun, R.; Gu, M.; Li, S.; Zhang, B.; Chi, Z.; Hao, L. shRNA-mediated silencing of Y-Box binding protein-1 (YB-1) suppresses growth of neuroblastoma cell SH-SY5Y in vitro and in vivo. PLoS One, 2015, 10(5), e0127224.
[http://dx.doi.org/10.1371/journal.pone.0127224] [PMID: 25993060]
[39]
Lim, J.P.; Nair, S.; Shyamasundar, S.; Chua, P.J.; Muniasamy, U.; Matsumoto, K.; Gunaratne, J.; Bay, B.H. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. Cancer Lett., 2019, 452, 119-131.
[http://dx.doi.org/10.1016/j.canlet.2019.03.014] [PMID: 30905819]
[40]
Chao, H-M.; Huang, H-X.; Chang, P-H.; Tseng, K-C.; Miyajima, A.; Chern, E. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β- catenin pathway. Oncotarget, 2017, 8(2), 2604-2616.
[http://dx.doi.org/10.18632/oncotarget.13733] [PMID: 27911878]
[41]
Gong, H.; Gao, S.; Yu, C.; Li, M.; Liu, P.; Zhang, G.; Song, J.; Zheng, J. Effect and mechanism of YB-1 knockdown on glioma cell growth, migration, and apoptosis. Acta Biochim. Biophys. Sin. (Shanghai), 2020, 52(2), 168-179.
[http://dx.doi.org/10.1093/abbs/gmz161] [PMID: 32047913]
[42]
Wang, H.; Sun, R.; Chi, Z.; Li, S.; Hao, L. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells. Mol. Cell. Biochem., 2017, 433(1-2), 1-12.
[http://dx.doi.org/10.1007/s11010-017-3011-3] [PMID: 28382490]
[43]
Stope, M.B.; Weiss, M.; Popp, S.L.; Joffroy, C.; Buck, M.B.; Mustea, A.; Brucker, S.; Wallwiener, D.; Knabbe, C. The pleiotropic factor Y-box binding protein-1 enhances the anti-proliferative efficacy of 4-hydroxytamoxifen and fulvestrant on breast cancer cells in vitro. Eur. J. Gynaecol. Oncol., 2019, 40(1), 16-18.
[44]
(a)Pecot, C.V.; Calin, G.A.; Coleman, R.L.; Lopez-Berestein, G.; Sood, A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer, 2011, 11(1), 59-67.
(b)Ohtsuka, M.; Ling, H.; Doki, Y.; Mori, M.; Calin, G.A. MicroRNA processing and human cancer. J. Clin. Med., 2015, 4(8), 1651-1667.
[http://dx.doi.org/10.1038/nrc2966] [PMID: 21160526] [http://dx.doi.org/10.3390/jcm4081651] [PMID: 26308063]
[45]
(a)Wilson, R.C.; Doudna, J.A. Molecular Mechanisms of RNA Interference. In: Annual Review Of Biophysics; Dill, K.A., Ed.; , 2013; Vol. 42, pp. 217-239.
(b)Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2), 281-297.
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]
[46]
Ors-Kumoglu, G.; Gulce-Iz, S.; Biray-Avci, C. Therapeutic microRNAs in human cancer. Cytotechnology, 2019, 71(1), 411-425.
[http://dx.doi.org/10.1007/s10616-018-0291-8] [PMID: 30600466]
[47]
Lu, J.; Li, X.; Wang, F.; Guo, Y.; Huang, Y.; Zhu, H.; Wang, Y.; Lu, Y.; Wang, Z. YB-1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA-216a. Exp. Cell Res., 2017, 359(2), 319-326.
[http://dx.doi.org/10.1016/j.yexcr.2017.07.039] [PMID: 28782557]
[48]
Xu, M.; Jin, H.; Xu, C-X.; Sun, B.; Song, Z-G.; Bi, W-Z.; Wang, Y. miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol. Ther., 2015, 23(1), 89-98.
[http://dx.doi.org/10.1038/mt.2014.197] [PMID: 25292190]
[49]
Bell, A.; Bell, D.; Chakravarti, N.; Ma, J.; Henton, N.; Prieto, V.G. Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin. Mod. Pathol., 2018, 31(11), 1744-1755.
[http://dx.doi.org/10.1038/s41379-018-0088-5] [PMID: 29955145]
[50]
Yang, F.; Wei, J.; Zhang, S.; Zhang, X. Shrimp miR-S8 suppresses the stemness of human melanoma stem-like cells by targeting the transcription factor YB-1. Cancer Res., 2017, 77(20), 5543-5553.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1375] [PMID: 28855207]
[51]
Guo, Y.; Pang, Y.; Gao, X.; Zhao, M.; Zhang, X.; Zhang, H.; Xuan, B.; Wang, Y. MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. Cancer Biomark., 2017, 18(1), 1-9.
[http://dx.doi.org/10.3233/CBM-160650] [PMID: 28035913]
[52]
Liu, S.L.; Sui, Y.F.; Lin, M.Z. MiR-375 is epigenetically downregulated due to promoter methylation and modulates multi-drug resistance in breast cancer cells via targeting YBX1. Eur. Rev. Med. Pharmacol. Sci., 2016, 20(15), 3223-3229.
[PMID: 27466996]
[53]
(a)Cocquerelle, C.; Mascrez, B.; Hétuin, D.; Bailleul, B. Mis-splicing yields circular RNA molecules. FASEB J., 1993, 7(1), 155-160.
(b)Qu, S.; Liu, Z.; Yang, X.; Zhou, J.; Yu, H.; Zhang, R.; Li, H. The emerging functions and roles of circular RNAs in cancer. Cancer Lett., 2018, 414, 301-309.
(c)Kulcheski, F.R.; Christoff, A.P.; Margis, R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J. Biotechnol., 2016, 238, 42-51.
[http://dx.doi.org/10.1096/fasebj.7.1.7678559] [PMID: 7678559] [http://dx.doi.org/10.1016/j.canlet.2017.11.022] [PMID: 29174799] [http://dx.doi.org/10.1016/j.jbiotec.2016.09.011] [PMID: 27671698]
[54]
(a)Qu, S.; Yang, X.; Li, X.; Wang, J.; Gao, Y.; Shang, R.; Sun, W.; Dou, K.; Li, H.; Circular, R.N.A. Circular RNA: A new star of noncoding RNAs. Cancer Lett., 2015, 365(2), 141-148.
(b)Geng, Y.; Jiang, J.; Wu, C. Function and clinical significance of circRNAs in solid tumors. J. Hematol. Oncol., 2018, 11(1), 98.
(c)Zhang, Y.; Liang, W.; Zhang, P.; Chen, J.; Qian, H.; Zhang, X.; Xu, W. Circular RNAs: emerging cancer biomarkers and targets. J. Exp. Clin. Cancer Res., 2017, 36(1), 152.
(d)Xuan, L.; Qu, L.; Zhou, H.; Wang, P.; Yu, H.; Wu, T.; Wang, X.; Li, Q.; Tian, L.; Liu, M.; Sun, Y.; Circular, R.N.A. Circular RNA: A novel biomarker for progressive laryngeal cancer. Am. J. Transl. Res., 2016, 8(2), 932-939.
[http://dx.doi.org/10.1016/j.canlet.2015.06.003] [PMID: 26052092] [http://dx.doi.org/10.1186/s13045-018-0643-z] [PMID: 30064463] [http://dx.doi.org/10.1186/s13046-017-0624-z] [PMID: 29096676] [PMID: 27158380]
[55]
Zhang, Z.; Xie, Q.; He, D.; Ling, Y.; Li, Y.; Li, J.; Zhang, H. Circular RNA: new star, new hope in cancer. BMC Cancer, 2018, 18(1), 834.
[http://dx.doi.org/10.1186/s12885-018-4689-7] [PMID: 30126353]
[56]
Lei, B.; Tian, Z.; Fan, W.; Ni, B.; Circular, R.N.A. Circular RNA: A novel biomarker and therapeutic target for human cancers. Int. J. Med. Sci., 2019, 16(2), 292-301.
[http://dx.doi.org/10.7150/ijms.28047] [PMID: 30745810]
[57]
Fang, J.; Hong, H.; Xue, X.; Zhu, X.; Jiang, L.; Qin, M.; Liang, H.; Gao, L. A novel circular RNA, circFAT1(e2), inhibits gastric cancer progression by targeting miR-548g in the cytoplasm and interacting with YBX1 in the nucleus. Cancer Lett., 2019, 442, 222-232.
[http://dx.doi.org/10.1016/j.canlet.2018.10.040] [PMID: 30419346]
[58]
Huang, S.; Zhang, X.; Guan, B.; Sun, P.; Hong, C.T.; Peng, J.; Tang, S.; Yang, J. A novel circular RNA hsa_circ_0008035 contributes to gastric cancer tumorigenesis through targeting the miR-375/YBX1 axis. Am. J. Transl. Res., 2019, 11(4), 2455-2462.
[PMID: 31105852]
[59]
Wang, L.; Wang, P.; Su, X.; Zhao, B. Circ_0001658 promotes the proliferation and metastasis of osteosarcoma cells via regulating miR-382-5p/YB-1 axis. Cell Biochem. Funct., 2020, 38(1), 77-86.
[http://dx.doi.org/10.1002/cbf.3452] [PMID: 31758574]
[60]
Tanaka, T.; Ohashi, S.; Saito, H.; Wada, T.; Aoyama, T.; Ichimaru, Y.; Miyairi, S.; Kobayashi, S. Indirubin 3′-oxime inhibits anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun., 2018, 496(1), 7-11.
[http://dx.doi.org/10.1016/j.bbrc.2017.12.106] [PMID: 29274785]
[61]
Li, C.; Wu, H.; Yang, Y.; Liu, J.; Chen, Z. Sesquiterpene lactone 6-O-angeloylplenolin reverses vincristine resistance by inhibiting YB-1 nuclear translocation in colon carcinoma cells. Oncol. Lett., 2018, 15(6), 9673-9680.
[http://dx.doi.org/10.3892/ol.2018.8592] [PMID: 29928343]
[62]
Gunasekaran, V.P.; Nishi, K.; Sivakumar, D.; Sivaraman, T.; Mathan, G. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer. Eur. J. Pharm. Sci., 2018, 116, 2-14.
[http://dx.doi.org/10.1016/j.ejps.2017.09.019] [PMID: 28916481]
[63]
Czolk, R.; Schwarz, N.; Koch, H.; Schötterl, S.; Wuttke, T.V.; Holm, P.S.; Huber, S.M.; Naumann, U. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells. Int. J. Mol. Med., 2019, 44(4), 1484-1494.
[http://dx.doi.org/10.3892/ijmm.2019.4296] [PMID: 31432139]
[64]
Diaz-Lagares, A.; Crujeiras, A.B.; Lopez-Serra, P.; Soler, M.; Setien, F.; Goyal, A.; Sandoval, J.; Hashimoto, Y.; Martinez-Cardús, A.; Gomez, A.; Heyn, H.; Moutinho, C.; Espada, J.; Vidal, A.; Paúles, M.; Galán, M.; Sala, N.; Akiyama, Y.; Martínez-Iniesta, M.; Farré, L.; Villanueva, A.; Gross, M.; Diederichs, S.; Guil, S.; Esteller, M. Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. Proc. Natl. Acad. Sci. USA, 2016, 113(47), E7535-E7544.
[http://dx.doi.org/10.1073/pnas.1608585113] [PMID: 27821766]
[65]
Zhao, X.; Liu, Y.; Yu, S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim. Biophys. Acta Mol. Basis Dis., 2017, 1863(7), 1805-1816.
[http://dx.doi.org/10.1016/j.bbadis.2017.04.014] [PMID: 28428004]
[66]
Su, W.; Wang, L.; Zhao, H.; Hu, S.; Zhou, Y.; Guo, C.; Wu, B.; Li, L.; Yang, Z.; Beer, D.G.; Chen, G. LINC00857 Interacting with YBX1 to regulate apoptosis and autophagy via MET and Phosphor-AMPKa Signaling. Mol. Ther. Nucleic Acids, 2020, 22, 1164-1175.
[http://dx.doi.org/10.1016/j.omtn.2020.10.025] [PMID: 33312753]
[67]
(a)Chen, Z.; Yu, W.; Zhou, Q.; Zhang, J.; Jiang, H.; Hao, D.; Wang, J.; Zhou, Z.; He, C.; Xiao, Z. A Novel lncRNA IHS promotes tumor proliferation and metastasis in HCC by regulating the ERK- and AKT/GSK-3β-signaling pathways. Mol. Ther. Nucleic Acids, 2019, 16, 707-720.
(b)Deng, S.J.; Chen, H.Y.; Ye, Z.; Deng, S.C.; Zhu, S.; Zeng, Z.; He, C.; Liu, M.L.; Huang, K.; Zhong, J.X.; Xu, F.Y.; Li, Q.; Liu, Y.; Wang, C.Y.; Zhao, G. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene, 2018, 37(44), 5811-5828.
[http://dx.doi.org/10.1016/j.omtn.2019.04.021] [PMID: 31128422] [http://dx.doi.org/10.1038/s41388-018-0382-1] [PMID: 29970904]
[68]
(a)Cho, K.H.; Jeong, B.Y.; Park, C.G.; Lee, H.Y. The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion. Arch. Pharm. Res., 2019, 42(6), 519-530.
(b)Yue, D.; Wang, Y.; Sun, Y.; Niu, Y.; Chang, C. C1QBP regulates YBX1 to suppress the androgen receptor (AR)-enhanced RCC cell invasion. Neoplasia, 2017, 19(2), 135-144.
[http://dx.doi.org/10.1007/s12272-019-01149-6] [PMID: 31004257] [http://dx.doi.org/10.1016/j.neo.2016.12.003] [PMID: 28107702]
[69]
Liao, L-Z.; Chen, C-T.; Li, N-C.; Lin, L-C.; Huang, B-S.; Chang, Y-H.; Chow, L-P. Y-Box binding protein-1 promotes epithelial-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. Int. J. Mol. Sci., 2020, 22(1), E224.
[http://dx.doi.org/10.3390/ijms22010224] [PMID: 33379356]
[70]
Prabhu, L.; Mundade, R.; Wang, B.; Wei, H.; Hartley, A-V.; Martin, M.; McElyea, K.; Temm, C.J.; Sandusky, G.; Liu, Y.; Lu, T. Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer. Oncotarget, 2015, 6(30), 29396-29412.
[http://dx.doi.org/10.18632/oncotarget.5120] [PMID: 26318844]
[71]
Martin, M.; Hua, L.; Wang, B.; Wei, H.; Prabhu, L.; Hartley, A-V.; Jiang, G.; Liu, Y.; Lu, T. Novel serine 176 phosphorylation of YBX1 activates NF-κB in colon cancer. J. Biol. Chem., 2017, 292(8), 3433-3444.
[http://dx.doi.org/10.1074/jbc.M116.740258] [PMID: 28077578]
[72]
Sechi, M.; Lall, R.K.; Afolabi, S.O.; Singh, A.; Joshi, D.C.; Chiu, S-Y.; Mukhtar, H.; Syed, D.N. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: Insights from in vitro and in vivo melanoma models. Sci. Rep., 2018, 8(1), 15726.
[http://dx.doi.org/10.1038/s41598-018-33879-w] [PMID: 30356079]
[73]
Hu, S.; Duan, Y-X.; Zhou, Q.; Wang, Y.; Lu, Q. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis. IUBMB Life, 2019, 71(7), 928-941.
[http://dx.doi.org/10.1002/iub.2028] [PMID: 30907986]
[74]
Khan, A.A.; Betel, D.; Miller, M.L.; Sander, C.; Leslie, C.S.; Marks, D.S. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol., 2009, 27(6), 549-555.
[http://dx.doi.org/10.1038/nbt.1543] [PMID: 19465925]
[75]
(a)Ly, S.; Navaroli, D.M.; Didiot, M.C.; Cardia, J.; Pandarinathan, L.; Alterman, J.F.; Fogarty, K.; Standley, C.; Lifshitz, L.M.; Bellve, K.D.; Prot, M.; Echeverria, D.; Corvera, S.; Khvorova, A. Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res., 2017, 45(1), 15-25.
(b)Shahabipour, F.; Barati, N.; Johnston, T.P.; Derosa, G.; Maffioli, P.; Sahebkar, A. Exosomes: Nanoparticulate tools for RNA interference and drug delivery. J. Cell. Physiol., 2017, 232(7), 1660-1668.
(c)Castanotto, D.; Rossi, J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature, 2009, 457(7228), 426-433.
[http://dx.doi.org/10.1093/nar/gkw1005] [PMID: 27899655] [http://dx.doi.org/10.1002/jcp.25766] [PMID: 28063231] [http://dx.doi.org/10.1038/nature07758] [PMID: 19158789]
[76]
Yi, R.; Doehle, B.P.; Qin, Y.; Macara, I.G.; Cullen, B.R. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA, 2005, 11(2), 220-226.
[http://dx.doi.org/10.1261/rna.7233305] [PMID: 15613540]
[77]
Lin, Z.; Lu, Y.; Meng, Q.; Wang, C.; Li, X.; Yang, Y.; Xin, X.; Zheng, Q.; Xu, J.; Gui, X.; Li, T.; Pu, H.; Xiong, W.; Li, J.; Jia, S.; Lu, D. miR372 promotes progression of liver cancer cells by upregulating erbB-2 through enhancement of YB-1. Mol. Ther. Nucleic Acids, 2018, 11, 494-507.
[http://dx.doi.org/10.1016/j.omtn.2018.04.001] [PMID: 29858084]
[78]
Zhao, X.; Zhang, W.; Ji, W. YB-1 promotes laryngeal squamous cell carcinoma progression by inducing miR-155 expression via c-Myb. Future Oncol., 2018, 14(16), 1579-1589.
[http://dx.doi.org/10.2217/fon-2018-0058] [PMID: 29517281]
[79]
Lasham, A.; Samuel, W.; Cao, H.; Patel, R.; Mehta, R.; Stern, J.L.; Reid, G.; Woolley, A.G.; Miller, L.D.; Black, M.A.; Shelling, A.N.; Print, C.G.; Braithwaite, A.W. YB-1, the E2F pathway, and regulation of tumor cell growth. J. Natl. Cancer Inst., 2012, 104(2), 133-146.
[http://dx.doi.org/10.1093/jnci/djr512] [PMID: 22205655]
[80]
Lasham, A.; Print, C.G.; Woolley, A.G.; Dunn, S.E.; Braithwaite, A.W. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem. J., 2013, 449(1), 11-23.
[http://dx.doi.org/10.1042/BJ20121323] [PMID: 23216250]

Rights & Permissions Print Cite
Article Metrics
76
2
© 2024 Bentham Science Publishers | Privacy Policy